2,3-Diaminobenzene-1-sulfonamide | 1378259-06-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3-Diaminobenzene-1-sulfonamide
• 英文别名: 2,3-diaminobenzenesulfonamide
• CAS: 1378259-06-3
• 化学式: C₆H₉N₃O₂S
• mdl: MFCD22371549
• 分子量: 187.22
• InChiKey: XYDLQHCWLVSLIN-UHFFFAOYSA-N

物化性质

• 沸点：
  467.8±55.0 °C(Predicted)
• 密度：
  1.522±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• [EN] AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL FORMULATIONS THEREOF FOR ORAL ADMINISTRATION<br/>[FR] LETERMOVIR AMORPHE ET FORMULATIONS PHARMACEUTIQUES SOLIDES DESTINÉES À ÊTRE ADMINISTRÉES PAR VOIE ORALE LE COMPRENANT
  申请人：AICURIS GMBH & CO KG

  公开号：WO2014202737A1

  公开（公告）日：2014-12-24

  The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30°C to 60°C, and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).

  本发明提供了非晶态Letermovir及其口服固体制剂（即刻释放制剂）。所述非晶态Letermovir适用于即刻释放制剂，当通过在挥发性有机溶剂（特别是丙酮）中滚筒干燥所述有机溶液，温度在30°C至60°C下，然后干燥获得的非晶态Letermovir，或者通过将所述非晶态Letermovir从水亲和性溶剂（选择自丙酮或乙腈）中沉淀到过量水中作为抗溶剂，然后过滤或离心获得的非晶态Letermovir进行分离。非晶态Letermovir的即刻释放制剂用于预防或治疗与疱疹病毒科相关的疾病的方法，优选与巨细胞病毒（CMV）相关，更优选与人类巨细胞病毒（HCMV）相关。
• Amorphous letermovir and solid pharmaceutical formulations thereof for oral administration
  申请人：AICURIS ANTI-INFECTIVE CURES GMBH

  公开号：US10442773B2

  公开（公告）日：2019-10-15

  The present invention provides for amorphous Letermovir and orally administrable solid pharmaceutical formulations thereof (immediate release formulation). Said amorphous Letermovir is suitable for immediate release formulations when isolated out of an organic solution by either roller-drying said organic solution in a volatile organic solvent, in particular acetone, at a temperature of 30° C. to 60° C., and subsequently drying the amorphous Letermovir obtained, or isolating said amorphous Letermovir by precipitation from water miscible solvents selected from acetone or acetonitrile into excess water as anti-solvent, and subsequently filtrating or centrifuging the amorphous Letermovir obtained. The immediate release formulations of amorphous Letermovir are intended for use in methods of prophylaxis or methods of treatment of diseases associated with the group of Herpesviridae, preferably associated with cytomegalovirus (CMV), even more preferably associated with human cytomegalovirus (HCMV).

  本发明提供了无定形 Letermovir 及其口服固体药物制剂（速释制剂）。将无定形 Letermovir 从有机溶液中分离出来时，可通过在 30° C 至 60° C 的温度下，在挥发性有机溶剂（尤其是丙酮）中滚筒干燥所述有机溶液，然后干燥得到的无定形 Letermovir，或将所述无定形 Letermovir 从有机溶液中分离出来时，可用于速释制剂、或将无定形 Letermovir 从丙酮或乙腈等可与水混溶的溶剂中沉淀到过量的水中作为反溶剂，分离出无定形 Letermovir，然后过滤或离心得到无定形 Letermovir。 无定形 Letermovir 的速释制剂用于预防或治疗与疱疹病毒科有关的疾病，最好是与巨细胞病毒 （CMV）有关的疾病，甚至最好是与人类巨细胞病毒（HCMV）有关的疾病。
• COMBINED SYSTEMIC AND TOPICAL TREATMENT OF DISORDERED TISSUES
  申请人：Quadex Pharmaceuticals, LLC

  公开号：EP2968228A1

  公开（公告）日：2016-01-20
• AMORPHOUS LETERMOVIR AND SOLID PHARMACEUTICAL FORMULATIONS THEREOF FOR ORAL ADMINISTRATION
  申请人：AiCuris Anti-infective Cures GmbH

  公开号：EP3010891A1

  公开（公告）日：2016-04-27
• IDENTIFICATION OF AN ALTERED THERAPEUTIC SUSCEPTIBILITY TO ANTI-HCMV COMPOUNDS AND OF A RESISTANCE AGAINST ANTI-HCMV COMPOUNDS
  申请人：AiCuris GmbH & Co. KG

  公开号：US20140193802A1

  公开（公告）日：2014-07-10

  The present invention relates to a method for the detection of an altered therapeutic response of a subject infected by HCMV to a treatment with a 3,4 dihydroquinazoline or N-3-[(4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide, a method for the detection of a drug resistance of a HCMV to a 3,4-dihydroquinazoline or N-3-[(4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide, and to a method for the detection of a mutation of a HCMV resulting in a drug resistance to a 3,4-dihydroquinazoline or N-3-[(4-[5-(6-aminopyridin-2-yl)-1,2,4-oxadiazol-3-yl]phenyl}sulfonyl)amino]-5-fluorophenyl}-1-cyanocyclopropanecarboxamide.